| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
|
92,933 |
72,445 |
$2.45M |
| 99213 |
|
49,829 |
42,234 |
$1.06M |
| 96367 |
|
26,204 |
16,486 |
$990K |
| 96413 |
|
25,788 |
16,569 |
$810K |
| Q5101 |
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram |
6,897 |
1,825 |
$807K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
262 |
175 |
$781K |
| J9271 |
Injection, pembrolizumab, 1 mg |
235 |
179 |
$701K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
24,529 |
14,695 |
$503K |
| 96372 |
|
30,975 |
15,812 |
$461K |
| 99233 |
Prolong inpt eval add15 m |
19,542 |
5,348 |
$444K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
7,668 |
5,153 |
$426K |
| 96365 |
|
15,046 |
10,203 |
$406K |
| J0897 |
Injection, denosumab, 1 mg |
770 |
744 |
$373K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
1,229 |
1,178 |
$353K |
| J9306 |
Injection, pertuzumab, 1 mg |
120 |
87 |
$338K |
| 99205 |
Prolong outpt/office vis |
6,146 |
6,135 |
$284K |
| 36415 |
|
11,465 |
8,920 |
$246K |
| Q5114 |
Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg |
147 |
89 |
$239K |
| 96360 |
|
7,095 |
4,295 |
$206K |
| Q5117 |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
133 |
103 |
$186K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
21,810 |
13,623 |
$174K |
| Q5129 |
Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg |
166 |
85 |
$149K |
| J1569 |
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg |
220 |
211 |
$128K |
| 96417 |
|
5,330 |
3,848 |
$123K |
| J1453 |
Injection, fosaprepitant, 1 mg |
684 |
440 |
$121K |
| J9171 |
Injection, docetaxel, 1 mg |
1,066 |
718 |
$119K |
| 99223 |
Prolong inpt eval add15 m |
2,840 |
2,736 |
$113K |
| 85025 |
|
14,827 |
11,310 |
$93K |
| 99232 |
|
5,923 |
1,338 |
$85K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
17,514 |
9,251 |
$84K |
| J1568 |
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg |
383 |
365 |
$79K |
| J9070 |
Cyclophosphamide, 100 mg |
160 |
102 |
$65K |
| 80053 |
|
2,972 |
2,237 |
$65K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
5,069 |
2,924 |
$63K |
| 96127 |
|
17,783 |
17,633 |
$61K |
| 99204 |
|
1,039 |
1,039 |
$56K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
2,136 |
1,412 |
$46K |
| 96402 |
|
2,832 |
2,695 |
$32K |
| 96375 |
|
2,981 |
2,036 |
$31K |
| 96415 |
|
2,625 |
1,852 |
$30K |
| J1437 |
Injection, ferric derisomaltose, 10 mg |
65 |
63 |
$29K |
| 99215 |
Prolong outpt/office vis |
1,812 |
1,650 |
$29K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
4,366 |
2,361 |
$24K |
| J1756 |
Injection, iron sucrose, 1 mg |
686 |
323 |
$20K |
| 99203 |
|
348 |
348 |
$18K |
| J3489 |
Injection, zoledronic acid, 1 mg |
551 |
516 |
$13K |
| 96366 |
|
2,350 |
1,959 |
$11K |
| 96361 |
|
977 |
701 |
$9K |
| 96374 |
|
379 |
347 |
$8K |
| J1566 |
Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg |
16 |
15 |
$6K |
| J1442 |
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram |
37 |
12 |
$6K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
2,669 |
2,354 |
$3K |
| J9045 |
Injection, carboplatin, 50 mg |
186 |
129 |
$3K |
| 96411 |
|
210 |
150 |
$2K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
14 |
12 |
$1K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
27 |
25 |
$1K |
| 43239 |
|
13 |
13 |
$1K |
| 80048 |
|
731 |
663 |
$337.59 |
| J9395 |
Injection, fulvestrant, 25 mg |
26 |
12 |
$320.96 |
| 80076 |
|
702 |
642 |
$287.87 |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
13 |
12 |
$275.94 |
| 82728 |
|
253 |
250 |
$218.93 |
| 96401 |
|
23 |
13 |
$94.74 |
| 82746 |
|
112 |
112 |
$83.84 |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
16 |
16 |
$46.00 |
| 82607 |
|
34 |
34 |
$41.50 |
| 96523 |
|
26 |
24 |
$35.09 |
| 85379 |
|
13 |
12 |
$22.75 |
| G9678 |
Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement |
355 |
350 |
$0.00 |